Just so we are clear, I do not think amarin is going bankrupt anytime soon. I was quoting the author of the forbes article which states that if amarin cancelled the study, the cholesterol experts believed the NHLBI should pick up the study. I don't think Amarin will cancel the study, therefore if the NHLBI did pick up the study, Amarin would cease to exist. All Hypothetical based on the Forbes article.
I am working on a letter and I believe it was you who mentioned the difference in label allowance between Lovaza and Vascepa. Can you provide me a synopsis on the difference or point me to articles that explain the difference?